Dipeptidyl peptidase-4 inhibitors and the risk of infection: A systematic review and meta-analysis of cardiovascular outcome trials

doi:10.4239/wjd.v15.i5.1011

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1605)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

WORD

HTML

1052

Figures (1-3)

121

Tables (1-1)

104

Sum=1321

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

152

Sum=192

May 15, 2024 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Diabetes. May 15, 2024; 15(5): 1011-1020
Published online May 15, 2024. doi: 10.4239/wjd.v15.i5.1011

Full Size Figure Download Figure

Figure 3 Risk of site-specific infections for dipeptidyl peptidase-4 inhibitors treatment vs control. A: Respiratory infections; B: Urinary tract infections; C: Abdominal and gastrointestinal infections; D: Skin structure and soft tissue infections; E: Bone infections; F: Bloodstream infection. DPP-4: Dipeptidyl peptidase-4.

Citation: Yang N, He LY, Liu P, Li ZY, Yang YC, Ping F, Xu LL, Li W, Zhang HB, Li YX. Dipeptidyl peptidase-4 inhibitors and the risk of infection: A systematic review and meta-analysis of cardiovascular outcome trials. World J Diabetes 2024; 15(5): 1011-1020
URL: https://www.wjgnet.com/1948-9358/full/v15/i5/1011.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i5.1011